IPSC Earnings Date: Nov 12, 2026 (Estimated) — Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IPSC's next earnings date?
Century Therapeutics, Inc. (IPSC) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.12 on revenue of $1.6M.
How did IPSC do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Century Therapeutics, Inc. posted EPS of -$0.17 versus the -$0.11 estimate, a miss of 41.7%. Revenue was $0 against a $2.2M estimate. The stock's 1-day post-earnings move was -4.9%.
How much does IPSC stock move after earnings?
IPSC beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.11 | -0.17 | -41.67% | $0 | ❌ Miss | -4.85% | -4.85% | -5.83% |
| 2026-05-13 | Q1 2026 | -0.17 | -0.11 | +35.29% | $0 | ✅ Beat | -0.44% | -7.42% | -2.18% |
| 2026-03-12 | Q4 2025 | -0.29 | -0.25 | +13.79% | $0 | ✅ Beat | -8.42% | -15.75% | -17.58% |
| 2025-11-13 | Q3 2025 | -0.35 | -0.40 | -14.29% | $0 | ❌ Miss | -17.54% | -8.24% | -0.99% |
| 2025-08-14 | Q2 2025 | -0.38 | -0.38 | +0.00% | $0 | ➖ Inline | +2.15% | -1.62% | -9.60% |
| 2025-03-19 | Q4 2024 | -0.44 | -0.43 | +2.27% | $4.2M | ✅ Beat | -5.66% | -4.63% | -6.74% |
| 2024-11-05 | Q3 2024 | -0.45 | -0.37 | +17.78% | $791,000 | ✅ Beat | +5.56% | +16.67% | +14.29% |
| 2024-03-14 | Q4 2023 | -0.55 | -0.65 | -18.18% | $268,000 | ❌ Miss | -7.20% | +3.09% | -19.55% |
Showing last 8 quarters.